[go: up one dir, main page]

ATE236873T1 - Biphenyl-hydroxamat matrix-metalloproteine inhibitor - Google Patents

Biphenyl-hydroxamat matrix-metalloproteine inhibitor

Info

Publication number
ATE236873T1
ATE236873T1 AT96940406T AT96940406T ATE236873T1 AT E236873 T1 ATE236873 T1 AT E236873T1 AT 96940406 T AT96940406 T AT 96940406T AT 96940406 T AT96940406 T AT 96940406T AT E236873 T1 ATE236873 T1 AT E236873T1
Authority
AT
Austria
Prior art keywords
hydroxamat
biphenyl
inhibitor
tnf alpha
matrix metalloproteinases
Prior art date
Application number
AT96940406T
Other languages
English (en)
Inventor
Stephen W Fesik
James B Summers Jr
Steven K Davidsen
George S Sheppard
Douglas H Steinman
George M Carrera Jr
Alan Florjancic
James H Holms
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE236873T1 publication Critical patent/ATE236873T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96940406T 1995-11-14 1996-11-13 Biphenyl-hydroxamat matrix-metalloproteine inhibitor ATE236873T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/555,690 US5665777A (en) 1995-11-14 1995-11-14 Biphenyl hydroxamate inhibitors of matrix metalloproteinases
PCT/US1996/018172 WO1997018188A1 (en) 1995-11-14 1996-11-13 Biphenyl hydroxamate inhibitors of matrix metalloproteinases

Publications (1)

Publication Number Publication Date
ATE236873T1 true ATE236873T1 (de) 2003-04-15

Family

ID=24218248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96940406T ATE236873T1 (de) 1995-11-14 1996-11-13 Biphenyl-hydroxamat matrix-metalloproteine inhibitor

Country Status (13)

Country Link
US (1) US5665777A (de)
EP (1) EP0874808B1 (de)
JP (1) JP2002504073A (de)
KR (1) KR19990067573A (de)
AT (1) ATE236873T1 (de)
AU (1) AU710666B2 (de)
DE (1) DE69627380T2 (de)
DK (1) DK0874808T3 (de)
ES (1) ES2196190T3 (de)
IL (1) IL123502A0 (de)
MX (1) MX9803809A (de)
PT (1) PT874808E (de)
WO (1) WO1997018188A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2250401A1 (en) 1996-03-29 1997-10-09 Thomas Budinger Enhancement of nmr and mri in the presence of hyperpolarized noble gases
PT968182E (pt) * 1996-08-07 2004-08-31 Darwin Discovery Ltd Derivados de acidos hidroxamicos e carboxilicos com actividade inibidora da mpm e do fnt
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
YU40999A (sh) * 1997-02-27 2002-06-19 American Cyanamid Company N-hidroksi-2-(alkil,aril ili heteroaril sulfanil,sulfinil ili sulfonil)-3-supstituisani alkil,aril ili heteroarilamidi, kao inhibitori za matrične metaloproteinaze
US6300514B1 (en) 1997-06-25 2001-10-09 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
TR199903287T2 (xx) * 1997-07-31 2000-09-21 Abbott Laboratories Matriks metaloproteinazlar�n�n ters hidroksamat inhibit�rleri.
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
EP1024134A4 (de) 1997-10-09 2003-05-14 Ono Pharmaceutical Co Derivate der aminobutansäure
US6288063B1 (en) * 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
FR2780402B1 (fr) * 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
WO2000044712A1 (en) * 1999-01-27 2000-08-03 Abbott Laboratories N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
EP1293202A4 (de) * 2000-02-10 2004-12-22 Ono Pharmaceutical Co Heilmittel für degenerative arthritis
US20030165431A1 (en) * 2000-07-13 2003-09-04 The Regents Of The University Of California Method for detecting macromolecular conformational change and binding information
US7061237B2 (en) * 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
US6652833B2 (en) 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
JP2004359546A (ja) * 2001-03-15 2004-12-24 Ono Pharmaceut Co Ltd ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および／または治療剤
WO2002074298A1 (fr) * 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
US7879911B2 (en) 2007-02-01 2011-02-01 Johnson Alan T Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
CN102267923B (zh) * 2010-06-04 2015-07-15 台北医学大学 组蛋白去乙酰化酶抑制剂
US20140271465A1 (en) * 2013-03-15 2014-09-18 Mallinckrodt Llc Matrix metalloprotease (mmp) targeted agents for imaging and therapy
EP3628661A1 (de) * 2013-06-27 2020-04-01 Lg Chem, Ltd. Biarylderivate als gpr120-agonisten
PH12017501029B1 (en) * 2014-12-24 2022-04-27 Lg Chemical Ltd Biaryl derivative as gpr120 agonist
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas
CN109820861B (zh) * 2019-03-13 2021-02-26 湖北科技学院 一种具有抗肿瘤活性的吩噻嗪类衍生物的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1548641A (de) * 1967-10-26 1968-12-06
US3755603A (en) * 1970-07-01 1973-08-28 Syntex Corp Biphenylyloxyacetic acids in pharmaceutical compositions
JPS525730A (en) * 1975-07-03 1977-01-17 Nippon Shinyaku Co Ltd Process for preparation of 1,3,5-tri-substituted derivatives
JPS5762239A (en) * 1980-08-26 1982-04-15 Hisamitsu Pharmaceut Co Inc Novel phenylacetic acid derivative
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US5036157A (en) * 1986-03-11 1991-07-30 Burroughs Wellcome Co. Aryl derivatives
KR927003520A (ko) * 1990-12-03 1992-12-18 죤 에드워드 베리만 펩티딜(peptidyl) 유도체
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
JPH05205730A (ja) * 1992-01-29 1993-08-13 Shin Kobe Electric Mach Co Ltd 薄形鉛蓄電池
AU3899193A (en) * 1992-04-07 1993-11-08 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
US5318964A (en) * 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
CA2140038C (en) * 1992-07-16 2004-02-17 Robert A. Innes Low temperature regeneration of coke deactivated reforming catalysts
US5310121A (en) * 1992-07-24 1994-05-10 Consilium Bulk Babcock Atlanta, Inc. Cold weather bulk stacker/reclaimer apparatus and method
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
ATE169621T1 (de) * 1993-03-16 1998-08-15 British Biotech Pharm Hydroxamsaeurederivate als metalloproteinase inhibitoren
NZ271893A (en) * 1993-08-23 1997-11-24 Immunex Corp Inhibitors of tnf-alpha secretion
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production

Also Published As

Publication number Publication date
MX9803809A (es) 1998-09-30
JP2002504073A (ja) 2002-02-05
DE69627380T2 (de) 2004-03-25
IL123502A0 (en) 1998-09-24
AU710666B2 (en) 1999-09-23
AU7729696A (en) 1997-06-05
EP0874808A1 (de) 1998-11-04
DE69627380D1 (en) 2003-05-15
DK0874808T3 (da) 2003-08-04
ES2196190T3 (es) 2003-12-16
WO1997018188A1 (en) 1997-05-22
KR19990067573A (ko) 1999-08-25
US5665777A (en) 1997-09-09
PT874808E (pt) 2003-08-29
EP0874808B1 (de) 2003-04-09

Similar Documents

Publication Publication Date Title
ATE236873T1 (de) Biphenyl-hydroxamat matrix-metalloproteine inhibitor
PL319503A1 (en) Peptide compounds and their therapeutic application as inhibitors
ES2194987T3 (es) Compuestos triciclicos utiles para inhibir la farnesil-protein-transferasa.
ES2157314T3 (es) Derivados triciclicos y su uso en productos farmaceuticos.
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
BR9811099A (pt) Inibidores de urocinase
DE69430465D1 (de) Hemmung uteriner Fibrose
CA2294171A1 (en) N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
DK0659416T3 (da) Inhibering af seborE og acne
IL129026A0 (en) Sulfonamide interleukin-1beta converting enzyme inhibitors
CO5180578A1 (es) Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas
ES2154669T3 (es) Uso de 2-fenil-3-aroilbenzotiofenos para la preparacion de un medicamento para la inhibicion de la degradacion del cartilago.
DK0659413T3 (da) Inhibering af CNS-problemer hos postmenopausale kvinder
DE69315699D1 (de) Inhibitoren gegen die aggregation von blutplättchen
CA2099867A1 (en) 2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
DK0720598T3 (da) Phenoxyphenylcyclopentenyl-hydroxyurinstoffer
NO970785D0 (no) Fremgangsmåte for benheling og fraktur-reparasjon
CA2315826A1 (en) Carboxyl acid substituted heterocycles as metalloproteinase inhibitors
NO970787D0 (no) Fremgangsmåte for hemming av primær endometrial hyperplasi
DK0606657T3 (da) Keterolacderivat med væsentligt nedsat gastrointestinal irritation og ulceration
DK0772438T3 (da) Anvendelse af benzothiophener til fremstilling af et medikament til reduktion af ardannelse under sårheling
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0874808

Country of ref document: EP

REN Ceased due to non-payment of the annual fee